David has enjoyed a progressive career in Pharmaceuticals and Biotech, spanning all aspects of commercialization. With experience in Dermatology, Neuroscience, and Diabetes, he has more recently specialized in Hepatology, Plasma Proteins, Haematology, and Rare Diseases. Whilst focusing on rare and ultra-rare therapy areas, he has learned how patients, payors, clinicians, manufacturers, and the NHS can align for better outcomes. David gained an MBA from Cranfield University and progressed through marketing and sales leadership roles into General Management. As GM for UK, Ireland & Nordics at Amicus Therapeutics, he has driven human-centered interventions, market solutions, and reimbursement success across Europe. Passionate about equitable healthcare and the critical role played by Health Care Professionals in achieving patient outcomes, he also serves as a Trustee of Cavell, supporting nursing and midwifery families.